Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

August 6, 2024

NASDAQ US Health Care Life Sciences Tools and Services earnings 62 min

Earnings Call Speaker Segments

Sallilyn Schwartz

executive
#1

Good day, everyone, and thanks for joining us for the earnings call covering the second quarter of 2024. On today's call, we'll go over the financial results that we published following the market close, and we'll also share some thoughts on what's happening commercially and on the regulatory front. After that, we'll open things up for a question-and-answer session. You can find our earnings release in the Investor Relations portion of our website, illumina.com. Speaking on behalf of Illumina with prepared remarks today are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob will share an update on how things are going at Illumina, and then Ankur will take us through the financial results for Core Illumina. A quick reminder: we divested GRAIL back in June of this year. If you want to go over GRAIL's second quarter financial results, or the consolidated Illumina numbers, those are available in our earnings release and in our SEC filings. This call is being recorded, and the audio will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity that we make on today's call to be protected under the Private Securities Litigation Reform Act of 1995. Statements that look ahead carry risks and unknowns. What actually happens or what we ultimately achieve could end up substantially different from what we've predicted or talked about. Every such statement reflects only what we know right now, and Illumina isn't on the hook to revise any of them later. For a clearer picture of the risks and unknowns that might make real outcomes diverge, please look at what Illumina submits to the Securities and Exchange Commission — that includes our latest Forms 10-Q and 10-K. Having said that, I'll pass things over to Jacob now.

Jacob Thaysen

executive
#2

Thank you, Salli. Good afternoon, everyone. During Q2, I kept up my meetings with customers and partners across the globe. They've shared the opportunities that have them excited, and we've talked through the challenges all of us are confronting in this climate. What's been most encouraging is watching those customers and partners bring their next-generation products to market. Illumina holds a distinctive position to back our customers' ambitions. Steady advances in science and technology let our customers imagine large-scale discovery programs that multiomics now makes achievable, and they're increasingly able to adopt whole genome sequencing, which delivers far greater insight. On top of that, there's a chance to weave genomics through the entire health care system to better patient outcomes, yet we must also assist our customers in coping with their present circumstances. Plenty of shifting forces remain in the world economy, and our stance has grown more measured. I hear often that customers feel limited in making major capital expenditures. We notice this too in longer sales cycles and in orders slipping later. For Illumina, that means balancing two crucial tasks. Task one is shoring up our own foundation. We're accomplishing this by continuing to roll out the NovaSeq X Series, which sets the stage for everything our customers and we aim to do going forward. We're also intensely focused on operational excellence and on refining how we operate the business. And task two is speeding up growth. Next week's strategy update will cover Illumina's vision going forward, our plan to deliver new dimensions of technology from our R&D vault, and our financial outlook covering the coming several years; for today's call, we'll concentrate on our second quarter results. In Q2, Illumina once again posted results above expectations, with Core Illumina revenue of $1.1 billion and non-GAAP operating margins of 22.2%, fueled by ongoing execution against our strategic priorities. Sequencing activity's continuing shift toward the NovaSeq X Plus produced a substantial jump in consumables this quarter. We also installed another 62 NovaSeq X Plus instruments. That said, we still see our customers closely managing their capital spend. Consequently, for the rest of the year, we're adding caution to our guide. Our view on the instrument business has grown more prudent to reflect sales cycles stretching further. Yet at the same time, our view on consumables is slightly stronger. Ankur will share more details on our adjusted guidance shortly. Now to how our regions performed in the second quarter. Americas revenue came in relatively flat year-over-year. Europe revenue fell 5%, reflecting the sizable backlog we cleared early last year after the X launch. AMEA revenue dropped 8%, and Greater China declined 35%. I've been discussing our three key priorities with you. I want to call out the progress Lumina's management team made toward those priorities during the second quarter. I'll begin with growing our revenue, where our emphasis has been on growing the number of instruments placed and assisting customers in getting the most out of those instruments. As I noted before, during Q2 we shipped 62 additional NovaSeq X Plus units, which lifts the cumulative X Plus installed base to 469. Our customers keep moving their work over to the NovaSeq X Plus, and the matching rise in sequencing activity is encouraging to us. Average yearly pull-through for the NovaSeq X Plus has now surpassed $1 million per instrument — a milestone worth celebrating. Shifting to mid-throughput. During Q2, we brought the XLEAP-SBS chemistry to our NextSeq 1k/2k, P1, P2 and P3 flow cells, which rounds out the P4 flow cell introduced earlier in the year. The XLEAP rollout has come in ahead of what we anticipated. Over 60% of the 1k/2k installed base has now received the software upgrade, which serves as an early signal of adoption. SBS chemistry brings better quality, more usable reads and shorter turnaround times, along with appealing pricing. Although customer enthusiasm for XLEAP is encouraging, the conversion into extra instrument purchases has fallen short of our expectations. Our mid-throughput category continues to be the one most affected by the macroeconomic climate. And we've observed that our sales cycles keep getting longer. Constrained capital spending is plainly the cause. Our win rates have held steady, and our pipeline has expanded; we'll keep standing behind our mid-throughput customers through this period and feel confident that extending XLEAP to NextSeq 1k/2k further reinforces our leadership position globally. Shifting to our second priority, achieving operational excellence; we're delighted that Everett Cunningham has joined as Chief Commercial Officer. Everett is already instilling a strong customer focus throughout the business, with operational excellence as a crucial foundation. As I've mentioned, my aim has been to align our organization so that our customers become heroes through delivery of the products, services and solutions that tackle their most urgent needs. After combining our marketing and commercial functions, we've rolled out a new commercial organizational design. We're positioning our teams to serve customers more effectively as their innovation partners. Teams now carry go-to-market expertise to speed up our multiomics capabilities and to commercialize and scale our software stack for research and clinical customers alike. This new structure will supply the alignment required to produce long-term results for both our customers and the business. In addition, earlier this year we told you that we're carrying out a portfolio optimization strategy aimed at generating productivity gains throughout our supply chain. As one recent illustration, we've pinpointed a set of products we intend to rationalize so we can sharpen our focus on more profitable offerings; naturally, we'll collaborate with our customers to ensure a smooth transition to other offerings within our portfolio. We're still making solid headway toward attaining greater operating leverage this year. Now to my third priority, which has involved working to resolve GRAIL as fast as we can. So, in June, the spin-off of GRAIL was finished, as you're aware, and these days GRAIL operates as a standalone publicly traded business. A minority position of 14.5% has been kept by Illumina. In the battle against cancer, GRAIL has a vital part to play. And although it's no longer affiliated with Illumina, our confidence in what lies ahead for it is unchanged. Through our sequencing technology and our services portfolio, we'll keep backing GRAIL. As we carry on executing the rollout of our fresh strategy, I'm certain we'll be positioned strongly to advance and to lead genomics' next period of growth and discovery. At this point, I'd like Ankur to walk through our Q2 results and outlook in greater detail.

Ankur Dhingra

executive
#3

Jacob, thanks, and good morning, everyone. My focus will be on non-GAAP results, which factor in stock-based compensation. Please review the GAAP reconciliation for these non-GAAP measures, as well as our consolidated financials, which now include GRAIL — both are available in today's release and in the supplementary data on our website. During the last 3 months, I've had the chance to work alongside Illumina teams in every function. The mission-driven nature of this team continues to impress me, and I can see transformation taking root at Illumina. I've also heard from many of our investors during a listening tour. While my prepared comments will focus on the financials and our forward view, I'd like to provide a bit more context. Revenue for Core Illumina in Q2 reached $1.1 billion. That figure represents a 6% decline compared with the same period last year, whether measured on a reported or constant currency basis, while rising 3% relative to the first quarter of 2024. We surpassed our guidance with these results. The outperformance stemmed mainly from growing demand for high-throughput sequencing consumables, as customers continued to expand their activity on NovaSeq X Plus. Partially countering that consumables strength were instrument shipments within our mid-throughput range that fell short of what we anticipated, since capital and cash flow limitations keep weighing on the purchasing choices our customers make. Core Illumina sequencing consumables brought in $737 million, matching the prior year's Q2 — and that quarter had been 2023's strongest for sequencing consumables. One standout during this year's second quarter was high throughput, where consumable shipments rose on both a year-over-year and a sequential basis. Consumables revenue ex grew 35% versus 2024's first quarter, a faster sequential pace than the double-digit increase recorded in Q1. To add a bit more detail around the transition: by Q2, roughly 45% of high-throughput giga bases sequenced, along with slightly above 25% of high throughput consumables revenue, came from NovaSeq X Plus. Regarding how quickly things are moving from the 6K to the X, what we've seen so far is that about five percentage points of revenue from high-throughput sequencing consumables shifts each quarter, on average, away from NovaSeq 6000 and toward NovaSeq X PLUS. Price effects keep getting smaller as this change continues. Should that pattern persist, by the middle of 2025 close to fifty percent of that consumables revenue ought to have migrated to the NovaSeq X, which would further lessen the pricing drag and, from then on, turn growing volumes into stronger revenue gains. Hopefully this extra detail is useful to you. Our disclosures about the NovaSeq X are being expanded so you can better see how far along we are in this key transition. Now on to sequencing activity. On our connected high- and mid-throughput platforms, total sequencing Gb output increased by over 40% versus a year ago and by roughly 10% from the previous quarter. We saw solid growth in activity among research customers as well as applied and clinical ones. Gb output isn't something that predicts near-term revenue, but it does give us a directional read on demand from underlying applications and on how heavily our instruments and consumables are being used. At Core Illumina, Q2 sequencing instruments revenue reached $116 million, up 5% sequentially yet down 40% year-over-year. Two factors drove that decline compared with a year earlier: one, we had fewer NovaSeq X placements, whereas Q2 2023 included a large volume of preorder shipments tied to the launch; and two, mid-throughput shipments came down as we expected, because constraints on capital and cash flow continue to influence how customers make purchasing decisions and hold back instrument placements. Revenue from Core Illumina sequencing service and other came in at $143 million, up 7% from the prior-year period, supported by higher revenue from strategic partnerships as well as increased instrument service contract revenue stemming from a bigger installed base. Moving on now to the other Core Illumina P&L lines. Core Illumina non-GAAP gross margins came to 69.4% in the quarter, which is 240 basis points better than a year ago. That robust gross margin result stemmed mainly from a more favorable revenue mix in sequencing consumables and, notably, from carrying out our operational excellence programs, which boosted productivity and produced cost savings. Core Illumina non-GAAP operating expenses totaled $516 million, a $15 million decrease from a year ago, reflecting lower head count and a number of other cost containment efforts. Taken together, Core Illumina non-GAAP operating margin reached 22.2% in Q2 2024 versus 21.2% in the same period last year. That was comfortably ahead of our 18% guidance and above our own expectations, thanks to revenue that exceeded what we anticipated, gross margin that beat expectations and progress our organization has achieved in cutting operating expenses. Taking a look below the operating income line, you'll see that Core Illumina's non-GAAP other expense for Q2 was $13 million. That figure includes 11 days' worth of interest expense tied to the $750 million delayed draw term loan, which we drew down in full on June 20, 2024. Core Illumina's non-GAAP net income for the second quarter reached $174 million, which works out to $1.09 per diluted share. For the quarter, the Core Illumina non-GAAP tax rate was 24.2%. Our non-GAAP weighted average diluted share count for Q2 was approximately 159 million. Now let's turn to Core Illumina cash flow and balance sheet items for the quarter. Cash flow from operations totaled $243 million. Capital expenditures totaled $30 million, while we generated $213 million in free cash flow. We ended the quarter holding roughly $994 million across cash, cash equivalents, and short-term investments. Turning now to our outlook for 2024: even though Q2 gave us reason for optimism, the balance of the year presents both positives and negatives. On the negative side, our customers remain limited in their capital spending. On the positive side, our Consumables segment, especially high-throughput, keeps performing well, driven by the NovaSeq X transition. Given all this, we're bringing down our revenue forecast for the back half of the year, with Instruments taking the biggest hit. For the full year, Core Illumina revenue should now be down 2% to 3% versus 2023, or 1.5% to 2.5% if you strip out currency effects. About half of the cut relative to what we previously guided comes from softer expectations for China and the rest of Asia. The other half reflects scaled-back assumptions for mid-throughput instruments and NovaSeq X shipments. On the instruments versus consumables split, taking the midpoint of our Core Illumina revenue range, sequencing instruments revenue would drop by a rate in the mid-30s compared with 2023. Sequencing consumables revenue is now tracking to grow toward the upper end of the low single-digit range against 2023; and with that, let me turn to the rest of the P&L. Illumina has managed to carry out the operational excellence initiatives we laid out, which has produced operating leverage beyond what we had anticipated. So we are lifting our Core Illumina non-GAAP operating margin guidance to between 20.5% and 21%. That captures the margin expansion we saw in Q2 2024, and we are additionally lowering our projected operating expenses for the back half of the year. We keep moving forward on our expense actions and on a number of operational excellence initiatives within our internal clinical continuous improvement program. Under that continuous improvement program, we have now started several new initiatives, and we anticipate they will generate another $200 million in expense savings across the coming few years; we will cover this more thoroughly during the upcoming strategy update. Also, we anticipate the Core Illumina non-GAAP tax rate will come in at roughly 25%. And finally, we are providing guidance for Core Illumina non-GAAP diluted earnings per share between $3.80 and $3.95 for the full year 2024. That range accounts for second half interest expense tied to the $750 million delayed draw term loan that we established in June of this year; for the third quarter of 2024, we anticipate Core Illumina revenue between $1.075 billion and $1.085 billion. Most of that decline compared with a year ago comes from shipping fewer NovaSeq X instruments, which mirrors how much backlog we worked through following the launch. Looking at the third quarter, we expect Core Illumina non-GAAP operating margin to land near 20%. The step down from the second quarter is driven largely by lower revenue along with project spending that shifted out of Q2; for third quarter non-GAAP Core Illumina, we're anticipating a tax rate around 25% and diluted EPS in the range of $0.80 to $0.90, and that figure again reflects the interest expense; having said that, I'll turn things over to Jacob for his closing remarks. Thank you.

Jacob Thaysen

executive
#4

Thank you, Ankur. Prior to opening the floor for questions, I'd like to take a few minutes to discuss what we've recently rolled out; over the course of 26 years, the most valuable thing Illumina possesses has been the engine driving our innovation. A case in point from this quarter is the release of the newest iteration of our DRAGEN software, bringing meaningful upgrades to the tools we use for analysis. Customer choices are now heavily influenced by bioinformatics, and this fresh version delivers our most precise multi-genome mapping capability, a leap forward in machine learning, plus the capacity to genotype challenging genes, which reveals richer insights. Moving forward, it's a thrill to reveal the upcoming set of NovaSeq X offerings. You may remember that the NovaSeq X Series, introduced in late 2022, is made up of 2 platforms: the NovaSeq X Plus, which has been delivered worldwide since March 2023; and the NovaSeq X, our single-flow cell high through-put sequencer aimed at buyers seeking a cheaper way into the X Series. Shipping for the X starts in Q4 of this year, and it can be upgraded to the X Plus; also during Q4, we're rolling out 100-cycle and 200-cycle 25B flow cells built for high-output counting uses like single cell and proteomics. On top of that, the upcoming software refresh for the NovaSeq X and X Plus will deliver higher yield along with other gains. I'm equally enthusiastic about the chances Illumina has to keep powering the multiomics ecosystem. There's more to come next week, but a standout moment recently was buying Fluent BioSciences, an organization whose single-cell technology sources and labels intricate cell mixtures so they can be prepared for sequencing. Thanks to Fluent's method, single-cell analysis becomes reachable for a wider group of buyers. Alongside the dedicated multiomics software offering gained through our Partek purchase, Fluent's offering forms one more piece in our push to deliver greater value to buyers by bringing their workflows even closer together. Our customers, we believe, should be free to choose whichever tools suit them best. That's why Illumina stays an open NGS platform, and we're dedicated to keeping up and standing behind the single-cell partnerships we already have. I'm eager to discuss our vision, our strategy and our financial outlook in greater detail next week during our strategy update. This virtual gathering happens on Tuesday, August 13. Kindly sign up via our Investor Relations website. We appreciate your presence today. I'll hand things over to the operator now to begin the Q&A.

Vijay Kumar

analyst
#5

Congratulations on the solid execution. Jacob, there's a lot of information in the deck. If I simply take the guidance and connect it to what you said about Nova X, the pull-through came to roughly $1 million. However, I believe there were some specifics regarding how much data X generates compared with the revenue it contributes. Is that gap—essentially the pricing effect—the way we should think about modeling this shift? Regarding the revised guidance, I didn't notice an orders figure for X. What portion of this change stems from high-throughput versus mid-throughput on the instrumentation side?

Jacob Thaysen

executive
#6

Thank you, Vijay, and I appreciate what you said about the strong quarter as well. Yes, we wanted to give a bit more insight into how to better model what we're seeing. First and foremost, we're definitely very happy that we've now hit the milestone of $1 million in annual pull-through on the X. And I think the information you also got from Ankur—and Ankur can offer a bit more insight here—is precisely meant to help guide you further on where we stand, where we're headed, and how the pricing versus volume effect is playing out. So, Ankur?

Ankur Dhingra

executive
#7

Right, absolutely. Vijay, as you noticed, we've included additional disclosures, and the reason is to assist everybody in reasoning about this transition. I'll simply present it the way I did in the script. Regarding the shift from 6k over to NovaSeq X, our statement is that within high-throughput, approximately 45% of consumables volume is currently on X; thus we're approaching about 0.5 point. So during the back half of this year, should that trajectory continue, half the volume would have transitioned to NovaSeq X. Another thing I put in was that the speed of this mix shows around 5 points of mix moving from 6k to NovaSeq X each quarter. Should that trajectory continue, then by next year we ought to reach roughly half of revenue originating from NovaSeq X. So that's how the trajectory looks. On your question about volume growth, indeed, total Gb sequenced came in at about 40%. That covers high-throughput and mid-throughput. And when you consider high-throughput revenue growth of roughly 1%, the difference is essentially the pricing and mix change effect.

Conor McNamara

analyst
#8

And a quick follow-up on that point. So, doing some basic arithmetic here — if volumes rose 40% while sequencing consumables stayed flat, that implies roughly a 40% drag from pricing. Should we expect that same sort of pricing headwind as the 5% conversion carries on? Or was it — is it larger in the early days of the NovaSeq X launch? I'm just trying to get a handle on what the pricing headwind is going to be.

Ankur Dhingra

executive
#9

Yes, let me take that one. So it is bigger early on, and as more volume shifts to X, the pricing effect keeps shrinking; that's mainly how I'm trying to frame the data. If you step back and look at it holistically, a move from 6k to X would have produced, all-inclusive, a price decline on a Gb-to-Gb basis of easily over 60% to 70%. And as that move keeps going, our baseline keeps declining, correct? So as the mix gets better as we reach — getting to the halfway volume transition point in the back half of this year. And now, based on that projection, it could reach the halfway revenue transition point by mid next year, and the price impact keeps declining.

Conor McNamara

analyst
#10

One more brief question about pricing, if I may. On the equipment side, are any price changes showing up, assuming you had to quote a figure? Or has it stayed fairly steady?

Jacob Thaysen

executive
#11

Correct. Broadly speaking, what we have observed — my guess is you mean the NovaSeq X Plus — is pricing that has remained largely unchanged. That is precisely the reason we are bringing out the NovaSeq X, since it offers a reduced price point for those customers facing capital limitations yet who still wish to obtain access to the NovaSeq family of instruments — the NovaSeq X Series of instruments. The wonderful part is that this lets them, at a later point in time, move up to the NovaSeq X Plus so they can benefit from both flow cells; therefore, we anticipate some customer interest in this regard later in the year, at the moment we introduce the NovaSeq X Plus — NovaSeq X.

Patrick Donnelly

analyst
#12

Jacob, perhaps a question about that $200 million cost reduction program — I realize you'd probably rather hold some details back until next week, I'm sure. Still, could you speak briefly about, first, the timing? And then secondly, where the opportunities are appearing? From conversations with investors, plenty of them have zeroed in on that R&D line. The key question is whether you folks are prepared to treat that as a lever once more, above 20% here? Could you address, again, whether any areas are strictly forbidden when it comes to cutting costs? And where your attention is going for those expense controls? It really seems as though the P&L holds plenty of potential. So I would enjoy exploring that a little.

Jacob Thaysen

executive
#13

Yes, I'll begin by stating that nothing is strictly forbidden; every component of the P&L is under review, and the $200 million reflects that as well; we are not — right now, we are not offering any details regarding the timing of this. What I can share, though, is that every element is being examined, and next week we'll give you further details. Turning to R&D, we keep assessing the way we wish to structure things or the way our R&D funds get spent. To share a bit of how I think about R&D, internally we examine every R&D project and assess its worth using rigorous metrics, such as NPV and ROIC. That's what I rely on too — as you're aware, my background is in R&D — so rather than being guided merely by a total figure, I'm genuinely concentrating on the programs that deliver overall growth for the business. Naturally, that also generates shareholder value. Consequently, we aren't working from a tops-down budget, which means we're examining this in a very, very granular way as well. I believe, Ankur, perhaps you'd like to add a bit more regarding the...

Ankur Dhingra

executive
#14

Yeah, absolutely. Like we mentioned, we'll probably provide a few additional specifics at the strategy session next week. What we're presenting here, though, is the actions we're taking as part of a plan to expand margins over multiple years. And we'll concentrate on every area that can help deliver a cost structure that's structurally improved and sustainable for the company over the long term. So there's more to come, but the emphasis is on all opportunities across every line.

Doug Schenkel

analyst
#15

Perhaps I should just slice the model in another, more straightforward manner. When I examine the trend across several quarters, consumable revenue appears to have reached its lowest point during Q4, hitting $687 million. Then it rose to slightly below $700 million in Q1. At present, we've climbed to a bit under $740 million in Q2. Although your guidance indicates instruments will decline by more than 30% compared to the same period last year, it appears you're anticipating instrument revenue to level off somewhere around $110 million to $120 million each quarter throughout this year. So if we assume nothing suggests some unexpected significant shift there, and we jump ahead to the following year, with Instrument revenue basically holding steady at these amounts while Consumables keep rising quarter by quarter as the installed base grows and usage volume evidently keeps increasing, if I'm simply reducing the calculation to basics, wouldn't that mean you'd need to get back to revenue growth in the mid-single-digit range or higher next year? Or am I getting something wrong? I'm not requesting guidance, and I'm not asking you to jump ahead of yourself before the Analyst Day happening next week. But purely from a math standpoint, what might I be overlooking?

Jacob Thaysen

executive
#16

Doug, I believe your assumption is correct, and as we mentioned before on that point, we think consumer growth serves as the proper signal for shifting toward improved company performance. I still believe it's premature to discuss '25 in detail. After all, over the past few days we've witnessed plenty of shifting factors. A U.S. election is on the horizon. Questions remain about events in the Middle East. Naturally, interest rates—we'll find out where they head. But obviously, we're making every effort to return to a far stronger growth path than what we've experienced over the last several years.

Ankur Dhingra

executive
#17

Yeah. And the one thing I'd tack on, Doug, is that you're zeroing in on the correct metrics. That's precisely the lens we're using for that business too. And like Jacob mentioned, there are plenty of shifting pieces right now. You've all seen the latest macro data points. So it's premature to make a call on 2025; however, the patterns we're observing with the X transition, with high-throughput consumables, plus the reality that pricing's effect ought to keep diminishing or get smaller as time goes on — those are all favorable elements, correct? During this year, another thing we've noticed is that total Gb output growth across the first half has been quite robust. Q1 came in above 35%; at this point we're looking at above 40%. When you check the prior several years — roughly the 5-year average — that figure sat closer to the 20s up to mid-20s range too; so there are multiple shifting pieces. The business's fundamentals appear to be heading the right way, yet it's still premature to make a call for '25.

Dan Arias

analyst
#18

Ankur or Jacob, in what way is the clinical community progressing toward adoption of the X? After that, what sort of expectations ought we to hold regarding those labs that take up the 25B kit? Also, assuming those two developments arrive afterward compared with the research community, would that create an added headwind during the back half of the year or in '25, if you must then begin considering pricing pressure in that area? Alternatively, is it your view that a certain point existed where elasticity within clinical markets is genuinely a topic you folks discuss? Do you believe that could begin benefiting you as we move into next year?

Jacob Thaysen

executive
#19

Yes. Naturally, we keep observing that the academic setting is — the academia setting has progressed toward the X more quickly than the clinical side has, and there is a solid justification for that. As you are aware, your products and your assays must be validated on the X prior to placing it into full production mode. What we have observed is that the approach taken by numerous clinical customers of ours has involved retaining their presently validated products or assays on the 6k while truly concentrating on the new assays. And across the past few weeks, you have actually seen a handful of launches involving new assays reaching the market. So that is beginning to become visible. In fact, we hold the belief that this will be — the majority of our — and essentially every one of our large clinical customers already possesses multiple access within their laboratories. Thus we do not — we are not anticipating any substantial shift or fluctuation during transition. Our view is that it will remain fairly steady across the coming stretch of time. So a particular change in trajectory does not worry me much.

Tycho Peterson

analyst
#20

I'd like to dig into a few of those mid-throughput remarks. I understand you're referring to capital cash flow when the rate is steady. Could you expand a bit on why you don't view that as a competitive problem?

Jacob Thaysen

executive
#21

Yes. No, we can definitely do that; and I believe we've also — first off, I'd say that we — as I said earlier, we keep taking competition very seriously. But I also said earlier that we have faced competition; this isn't the first time we're encountering it. Illumina encountered competition throughout this entire period. That said, we're taking — I'm taking a very different approach here and a proactive stance compared with what I saw when I joined the company. And we're beginning to see that generate meaningful impacts, both in the marketplace and in the company's culture. At least in the mid-throughput space, we do see that with this, the area with the most intense competition, China remains an issue here. There is competitive pressure here, but it hasn't truly shifted across the past quarters. Second, we are tracking every deal extremely closely; and we actually have very good visibility into where we stand on this right now; and if you examine it, we actually don't see any shift in the win rates. We actually stay quite range-bound across the last few quarters. So we don't see any genuine change in this; and as a result, we're attributing the largest portion of this to the economic environment.

Tycho Peterson

analyst
#22

All right. Then I have one more question. If you anticipate that by the middle of 2025, 50% of high-throughput Consumables will move over to X. I suppose, what additional share do you think will make that switch, and as a result, how much will the pricing strain need to flow through the model? And ought we to think of 2025 as a year that comes in under the long-range plan you're about to share?

Ankur Dhingra

executive
#23

Yes. Let me verify we have the correct figure here. From a volume standpoint, we ought to pass the midpoint during the back half of 2024. In Q2, as an example, we observed 45% of the volume arriving on X. For the 2025 references, 50% of the revenue ought to move across into X. And for each 5, 7-point mix, the effect of the price keeps declining while the contribution of that volume to revenue keeps rising. Particularly regarding, Tycho, 2025, we will discuss it. There will be a number of moving pieces; so we will address that once we reach the guidance point.

Tycho Peterson

analyst
#24

All right. And one quick point of clarity before I leave. Regarding that $200 million continuous improvement program, is the cost savings you'll detail at the Analyst Day part of it? And does that span 3 years?

Jacob Thaysen

executive
#25

Yes, we'll share further detail next week, but we intend to return and offer a thorough picture of both — our outlook on growth, how we anticipate applying that growth across the coming few years — naturally, regarding our margin expansion, and also our earnings power. So we'll deliver that entire picture over a 3-year timeframe.

Subhalaxmi Nambi

analyst
#26

And Ankur, I appreciate you giving us that extra detail regarding NovaSeq X and 6000 dynamics. One thing I wanted to ask — building on <<inaudible>>, which concerns NovaSeq X placements done offshore — is what proportion is clinical as opposed to research? Then, among clinical buyers, how many are first-time purchasers versus those replacing something? For customers who already exist and then buy X, are they shifting assays they already run onto X? Or do they mostly employ X for brand-new assays, the kind that usually call for deeper sequencing or virus sequencing? I raise that final point since utilization of 6000 does appear to be fairly <<inaudible>>.

Ankur Dhingra

executive
#27

Yes. Subhu, whether we've given that specific data mix splitting clinical from research segmentation, I'm not sure. In general we've described it as approximately half and half, I think, right, Salli, historically, though it isn't something we report on a continuing basis. Then regarding our clinical customers moving to X, the usual pattern still centers on newer tests, since the bulk of clinical customer emphasis from an X standpoint is on creating newer tests for X when it launches, after which you observe the high volume. And Jacob can add more color there.

Jacob Thaysen

executive
#28

Yeah, that's exactly right. And what we're noticing is that most of these new tests tend to be more sequencing-intensive. Naturally, there's a desire to obtain additional samples, but sample count isn't the sole factor at play here. We're definitely observing a lot of our customers seeking bigger panels; this will involve whole genome sequencing, with things like new insights—for instance, <<inaudible>> insights within your panels, and so forth—as well as deeper sequencing on its own. So that's the pattern in the clinical area. When you turn to academia, plenty is happening, particularly around single cell and various other domains. At this point we're beginning to witness a rise in spatial, which demands far greater sequencing intensity; so that's the situation as it stands.

Puneet Souda

analyst
#29

So, starting with the first one — I'm just trying to get a handle on mid throughput — is cost per gigabase something you can pull to bring costs down soon, so you compete better in that market? Or is it your view that the Nova X remark you gave at the end, Jacob, rather than the X-plus with a single flow cell — do you think pricing there is in fact heading lower to close what might be a gap with a rival in the mid-throughput space?

Jacob Thaysen

executive
#30

Yeah, I'd say — appreciate that. I'd say both. What I mean is that with the NovaSeq X using 1 flow cell, every application can be run. You're able to run a 25B flow cell and get the full benefit of the pricing we offer at the NovaSeq Plus level of flow cells. Still, when it comes to mid throughput, we definitely have room to lean on our pricing should that be needed. But I do think that — yet that is — yet in fact, that in fact delivers a lot of — we've already set that pricing at an extremely, extremely competitive point. Even so, I do think it's more complex than just that. And although I absolutely believe there are many excellent people on the teams at our competitors, I think at times we all get trapped in definitions of claims that are far too narrow. So at times, we observe interim workflow steps being viewed purely through a claim lens; we're seeing applications that are limited, or even performance resting on very limited data. And I think in pretty much every case, they are meeting the entire computational chain from DRAGEN, which also meaningfully boosts quality and cuts the overall workflow costs. So when you factor in all of that, and even if we charge a premium cost per gigabase, you'll in fact find that across full workflow cost, application breadth and complete computation power, we remain highly differentiated. And I in fact think our customers see that. I agree. We could communicate this better, but we'll invest more time next week as well, offering more insights on it. And also, more of the differentiations we'll deliver, for both mid-throughput and high-throughput, by showing you examples of what sits in our R&D vault.

Puneet Souda

analyst
#31

All right, that's useful. Next, regarding the commercial organization, I'm simply attempting to figure out why this is the correct moment to make a change. I'm just trying to get a sense of what some of those changes involve. Are you — is there some shift you're pushing within the quota-bearing sales force currently in place? Certain parts of that have performed quite well in the past. Clearly, you've got a truly strong product available in the market. Still, I'm curious what's behind this? And what do those changes consist of?

Jacob Thaysen

executive
#32

Yeah. I mean, I believe what we already made public was that prior to Everett joining, I sensed it mattered to unite our marketing folks with our sales folks. So beginning at the highest level, uniting those 2 teams produces a certain synergistic outcome as well. You'll bring the leadership group into alignment, and we've now accomplished that on the average. So there's 1 commercial team, and that's the first point. Second, we've examined more closely how we can truly push additional quota-carrying individuals out into the field. And how can we guarantee we possess even stronger application abilities at this point as we speed ourselves toward multiomics, and also, in the area where we think informatics ought to have a still larger role. So this concerns less altering the regions and the regional structure, and more — putting additional feet on the ground, as the saying goes.

Puneet Souda

analyst
#33

Understood, and for my final question, I'd like to ask this. What's the right way to frame the total pull-through? We're already past $1 million. Based on your calculations, where do you expect that figure to eventually settle?

Jacob Thaysen

executive
#34

Yeah. Well, we're definitely quite pleased that the X Series is now generating $1 million each year; and although we expect it will — we don't view this as the final level or the steady state. So our belief is that it can rise further. We're also seeing customers achieve significantly more than that already; so it's encouraging to watch how far this might develop. However, we don't have — or at least we aren't prepared to provide a detailed outlook regarding where we think it might end up right now.

Sung Ji Nam

analyst
#35

This one is for Ankur. Could you give us additional detail regarding what you expect for China, Greater China, and AMEA? Looking at how growth has moved across the recent quarters, it appears fairly steady; but I'm wondering whether your guidance — I believe you mentioned that half of it comes from China, Asia — so I'm curious about how your expectations have shifted compared with the prior quarter. Also, do you anticipate a meaningful decline in those areas moving forward?

Jacob Thaysen

executive
#36

Yes. Let me begin by saying, first of all, regarding China, it remains too soon to determine what part of the cycle we're in; based on what we observe, the economy remains soft and customers are still limited. So we — and we don't truly — as you also pointed out, we don't truly observe any shift — any material shift in how intense competition is in China. Still, it's a difficult market in which to operate. What genuinely excites me is that we have — and as I think was also mentioned on the previous call, we brought in our new head of Region for China, and she has now been in that role for slightly over a quarter. She is also very engaged in refining the commercial structure, as with the rest of the world, really concentrating on shifting more people into field roles from the back office. In addition, she is reworking partnerships and improving those sorts of relationships, and naturally, she keeps evaluating how we aim our pricing approaches for particular product groups, and lastly, she is bringing IVD, additional IVD products into China. So there is plenty we are doing in that market at present. And I believe that in time, this will reverse. However, right now, it's too soon to offer more detailed insights. I think perhaps, Ankur, you could share a bit more perspective on the rest of Asia?

Ankur Dhingra

executive
#37

Sure, I’ll add a few more details here, since this is something we factored into our guidance. Our earlier projections, along with what was expected for China, did not assume any meaningful rebound in that part of the business. That said, when you examine the sequential progression of that business, it did suggest some increase, even while it remains below the prior-year level. For the past 6 to 8 quarters, conditions in China have been soft. In fact, looking at Illumina overall on a year-over-year basis at the midpoint, the midpoint in my full-year guidance is now about 1.5 points lower on a constant currency basis, or 2 points on a constant currency basis. China accounts for a very large share of that — almost 2/3 — and in the areas where our business has been especially weak, we are not seeing any indications of recovery. There is a great deal of commercial activity from where we sit, and we are making changes within the team. But the broader environment there at the moment does not support going out and assuming any sort of growth in business volumes for the remainder of the year, so we have essentially removed that from the forecast and are working to reduce that risk.

Eve Burstein

analyst
#38

Thank you. Over the past several months, we have watched Quest and LabCorp each reveal or grow partnerships with one of the companies you compete against. Could you refresh our memory on how much of your revenue is generated by those two firms? And I could think of a few explanations for why their behavior might differ from that of your other clinical clients. For instance, my assumption is that a larger share of their testing involves LDTs and FDA-approved assays, which means fewer of the X boxes are required. Perhaps the fit is simply more natural. Still, why should we not interpret this as a strong indicator that you could lose meaningful share in the clinical market, rather than merely a possible revenue impact when and if assays move over to the X and X Plus?

Jacob Thaysen

executive
#39

Yes. My recommendation would be that you direct those questions about their choices to form collaboration agreements with other players in the NGS space to those companies themselves. Our focus is, above all else, on delivering the greatest quality to our customers. Because I believe there is a bit of excessive attention right now on a price point that applies to an extremely narrow application space. And that does not truly tackle what is possible for the patents you handle today or for whole genomes. Conversely, this is not solely a matter of offering a price; it is also about offering a product and a solution that customers trust the vendor can deliver and keep supporting; so there are far more factors that come into play here. And at Illumina, we will keep doing everything we can to deliver the finest solutions, concentrating not just on one piece of the workflow, namely sequencing cost, but on the total workflow cost and on giving our customers the highest quality of answers.

David Westenberg

analyst
#40

Could you discuss the pricing change with XLEAP? My understanding is that XLEAP on mid-throughput is backward compatible. I think you mentioned adoption at 60%. What's the right way to consider the real total dollar effect of that pricing shift? Could you address this year in particular within the guidance? I also have one follow-up, and then just one — apologies — one more clarification regarding throughput. Could you discuss the validation step needed for clinical moving from regular? Actually, two on that.

Jacob Thaysen

executive
#41

First, on the big picture, as we stated, 60% of our installed base has downloaded the software. That's what we view as a signal that people have strong interest in XLEAP chemistry. Yet we also observe considerable interest, especially in the P4. The P4 flow cell has been available for some time, but now it's also coming into the P1, 2, 3; we have a different price point, as we've likewise been discussing for XLEAP chemistry, which is among the interesting areas, but we also deliver higher sequencing quality and greater capacity; so Ankur, perhaps you can give a bit more insight into where we stand in the transition; but let me just address the validation — that depends on moving from XLEAP over to — from standard SBS chemistry onto XLEAP chemistry. It truly depends on the assays. Typically, though, you'll need to complete normal validation. That's simply what happens when you switch to other software or <<inaudible>> and you'll do that, and every clinical lab will understand how to proceed. However, there are no particular steps required on our side when moving from one to the other. Ankur, would you like to share more on where we are with the transition?

Ankur Dhingra

executive
#42

Correct — regarding the shift, moving from XLEAP to what we had before, or the earlier consumables, a pricing change is going to take place, yet it's considerably smaller and probably more proactive than what you've observed with the X side. So if you're modeling or looking ahead, the empty consumables business's volume represents a far, far smaller share of our P&L and revenue base than our ex consumables business does. So I'm not — when it comes to the effect on the total revenue line, it will be considerably smaller.

David Westenberg

analyst
#43

Understood. Then, a fast follow-up regarding Fluent. What is the plan when it comes to pricing? Is it possible to push pricing below that level? And regarding bundle pricing, do you have any ideas about how you'd approach it? And on the IP side, are you feeling fairly confident about IP? From what I understand, that's an emulsion step rather than a microfluidic one. So does that give you protection? I mean, there's been considerable IP activity in that area.

Jacob Thaysen

executive
#44

Yes. We're definitely quite thrilled about acquiring Fluent. And as you pointed out, we believe above all that Fluent's technology enables wider adoption of single cell. So there are definitely segments in the mid-throughput range where customers can readily enter single cell work, and patients at high volume where the cost per individual experience, per individual cell, is actually competitive and can definitely serve that market segment. It's still too soon for us to discuss how commercialization will be handled. But as we've said previously, we will obviously step in and introduce Fluent, which is a highly appealing option. We'll keep collaborating with every partner and every single cell provider across the industry, letting them offer something extremely competitive on our platforms as well.

Dan Brennan

analyst
#45

Jacob and Ankur, perhaps a quick point of clarification to start, followed by a question regarding consumables. On that clarification: my understanding is you indicated there isn't really much margin pressure once we actually shift into mid-throughput — is that right? The reason I ask is that our impression was, in fact, you laid out $9 per G, and I believe the on-label price for NextSeq could have landed somewhere in the teens or the low 20s; so perhaps you could address briefly how the margin effect plays out as your mid-throughput installed base takes on XLEAP?

Ankur Dhingra

executive
#46

Sure; what I'm telling you is that a margin drag will exist. The figures you're referencing are list prices, yet the on-market prices probably already sit somewhere other than where list prices are, and then secondly, regarding that margin drag, since the contribution mid-throughput consumables provide to our total revenue represents a comparatively smaller portion of my P&L, the impact of that drag across the entire Illumina P&L should be broadly manageable.

Jacob Thaysen

executive
#47

I'd add, though, that our R&D group, working alongside manufacturing, has really succeeded in bringing down what the XLEAP chemistry costs; as a result, it carries a reduced COGS, and therefore puts less pressure on margins, yes.

Dan Brennan

analyst
#48

Understood. Then, I realize you provided plenty of detail regarding volume during the presentation. But did you address — and I'm sorry if you already covered this somewhat more regarding the research first, the clinical side, such as revenue growth during the quarter? For instance, how did that segment for NGS? Also, any insight into what is baked into the '24 guidance between, say, research and clinical and, presumably, whatever competitive effect exists there, even though I suppose you see that you're truly succeeding at winning? I would assume it's more on the research side rather than the clinical side; so any insight you might offer there would be useful.

Jacob Thaysen

executive
#49

Yes. So typically we don't break that out, but I can share that we are expanding robustly on both sides of the academic and the clinical portion of the business.

Sallilyn Schwartz

executive
#50

We appreciate you being with us on this call. Just a note that you'll be able to find a replay in the Investors portion of our site; that wraps things up for today, and we hope to connect with you at our Investor Day coming up as well as other events.

Operator

operator
#51

Ladies and gentlemen, this concludes today's call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.